Opthea Limited

ASX (AUD): Opthea Limited (OPT)

Last Price

0.712

Today's Change

-0.018 (2.46%)

Day's Change

0.705 - 0.73

Trading Volume

30,742,999

Overview

Market Cap

876 Million

Shares Outstanding

1 Billion

Avg Volume

4,271,938

Avg Price (50 Days)

0.50

Avg Price (200 Days)

0.55

PE Ratio

-1.40

EPS

-0.51

Earnings Announcement

26-Feb-2025

Previous Close

0.73

Open

0.73

Day's Range

0.705 - 0.73

Year Range

0.3125 - 0.815

Trading Volume

30,742,999

Price Change Highlight

1 Day Change

-2.47%

5 Day Change

14.84%

1 Month Change

27.14%

3 Month Change

100.56%

6 Month Change

3.94%

Ytd Change

26.02%

1 Year Change

122.50%

3 Year Change

-47.26%

5 Year Change

-80.91%

10 Year Change

242.60%

Max Change

211.67%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment